Rest Of Latin America Cardiac Marker Testing Market (2026-2031)
The Rest Of Latin America Cardiac Marker Testing Market was valued at $27.4 Million in 2026 and projected to reach to $37.6 Million by 2031, representing a compound annual growth rate of 6.5%. Rest Of Latin America's cardiac marker testing market is positioned for steady growth driven by escalating cardiovascular disease incidence and expanding healthcare accessibility across the region.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Rest Of Latin America Cardiac Marker Testing Market Trends and Insights
- This steady expansion in Rest Of Latin America reflects increasing cardiovascular disease prevalence and growing healthcare infrastructure investment across the region.
- Rest Of Latin America is experiencing rising demand for rapid diagnostic solutions driven by improved access to point-of-care testing and heightened awareness of early cardiac event detection. The cardiac marker testing landscape in Rest Of Latin America is characterized by a shift toward high-sensitivity troponin assays and multiplex testing platforms.
- Rest Of Latin America's healthcare providers are increasingly adopting advanced diagnostic technologies to improve patient outcomes and reduce hospital readmission rates.
- Between 2026 and 2031, Rest Of Latin America will see accelerated adoption of automated testing systems in both hospital and laboratory settings, supported by regulatory improvements and cost-containment initiatives across the region..
Key Market Statistics
- CAGR (2026-2031) 6.5% CAGR
- Market Size, 2026 ~USD 27.4 Million
- Forecast, 2031 ~USD 37.6 Million
- Country Rest Of Latin America
Rest Of Latin America Cardiac Marker Testing Market Overview
Market Size & Growth :
Rest Of Latin America's cardiac marker testing market is valued at USD 27.4 million in 2026, expanding to USD 37.6 million by 2031, with a steady CAGR of 6.5% reflecting regional healthcare advancement.
Cardiovascular Disease Burden :
Rising prevalence of cardiovascular diseases across Rest Of Latin America is driving demand for cardiac marker testing as a critical diagnostic tool for early detection and patient management.
Healthcare Infrastructure Investment :
Increasing government and private sector investments in healthcare infrastructure across Rest Of Latin America are improving access to advanced cardiac diagnostic testing capabilities.
Regional Growth Dynamics :
Rest Of Latin America's 6.5% CAGR, while below the global 10.3% rate, reflects emerging market maturation and growing adoption of cardiac biomarker testing in secondary and tertiary care facilities.
Rest Of Latin America Cardiac Marker Testing Market Dynamics
- The market's 6.5% CAGR reflects gradual but consistent adoption of advanced diagnostic technologies in both urban and emerging healthcare settings. Key growth catalysts include increased awareness of cardiac health, rising healthcare expenditure, and improved laboratory infrastructure in Rest Of Latin America.
- As regional economies develop and healthcare systems modernize, demand for reliable cardiac biomarker testing will intensify, supporting market expansion through 2031 and beyond..
Related Ecosystem
In Vitro Diagnostics
Medical Devices
Key Takeaways
- Rest Of Latin America's cardiac marker testing market is valued at USD 27.4 million in 2026 and will reach USD 37.6 million by 2031 at a 6.5% CAGR.
- Rest Of Latin America is witnessing increased adoption of high-sensitivity troponin assays and multiplex diagnostic platforms.
- Growing cardiovascular disease burden and improved healthcare infrastructure are primary growth drivers in Rest Of Latin America.
- Rest Of Latin America's market is shifting toward point-of-care and automated testing solutions to enhance diagnostic efficiency.
Cardiac Marker Testing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | OTHER CARDIAC BIOMARKERS (Biomarker Type) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 10.3% from 2026 to 2031 |
| Largest Segment | SINGLEPLEX ASSAY (Assay Format) |
| Market Size Base Year (Billions) | ~USD 5.55 (2026) |
| Revenue Forecast (Billions) | ~USD 9.06 (2031) |
| Segments Covered | Product, Technology, Type, Indication, Biomarker Type, Point Of Testing, Assay Format, End User |
Rest Of Latin America Cardiac Marker Testing Market Report Segmentation
8 segment dimensions are covered across the global market.
By Product
- Instruments
- Reagents & Kits
By Technology
- Clinical Chemistry
- Immunoassay
- Immunoassays
By Type
- Chemiluminescence
- Contract Testing Laboratories
- Elisa
- Hospital Laboratories
- Immunofluorescence
- Lateral Flow Immunoassay
- Reference Laboratories
By Indication
- Acute Coronary Syndrome
- Atherosclerosis
- Congestive Heart Failure
- Ischemia
- Myocardial Infarction
By Biomarker Type
- Brain Natriuretic Peptide
- Creatinine Kinase-Mb
- High-Sensitivity C-Reactive Protein
- Homocysteine
- Myoglobin
- Other Cardiac Biomarkers
- Troponin I & T
By Point Of Testing
- Lab Tests
- Poc Tests
By Assay Format
- Multiplex Assay
- Multiplex Assays
- Singleplex Assay
- Singleplex Assays
By End User
- Academic Institutes
- Laboratory Testing Facilities
- Point-Of-Care Testing
Target Audience
- In Vitro Diagnostics Manufacturers : IVD companies need Rest Of Latin America market data to assess regional demand for cardiac marker assays, identify growth segments, and develop localized commercialization strategies.
- Healthcare System Administrators : Hospital and clinic leaders require market insights to justify cardiac diagnostic infrastructure investments, benchmark regional spending patterns, and optimize laboratory service offerings.
- Medical Device Distributors : Regional distributors need Rest Of Latin America-specific market forecasts to evaluate partnership opportunities, inventory planning, and sales projections for cardiac testing platforms.
- Healthcare Investors & Consultants : Investment firms and management consultants require detailed Rest Of Latin America market analysis to identify acquisition targets, assess portfolio companies, and guide healthcare sector investments.
- Laboratory Service Providers : Clinical laboratory operators need regional market data to understand demand drivers, competitive positioning, and growth opportunities for cardiac marker testing services in Rest Of Latin America.
Key Companies in the Rest Of Latin America Cardiac Marker Testing Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ABBOTT LABORATORIES | United States | Public Company | Diagnostic Products,Medical Devices,Nutritional Products, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing hardware, consumables, and services),Life Sciences (instruments, reagents, and genomic medicines),Diagnostics (clinical instruments, consumables, and software), |
| SIEMENS HEALTHINEERS AG | Germany | Public Company | Imaging,Diagnostics,Varian (Oncology), |
| THERMO FISHER SCIENTIFIC | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| BIO-RAD LABORATORIES | United States | Public Company | Life Science,Clinical Diagnostics, |
| BIOMéRIEUX SA | France | Public Company | Clinical microbiology (culture media, VITEK, VITEK MS, API, ETEST, BACT/ALERT),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS, EPISEQ),Immunoassay and sepsis (VIDAS, Hybiome CLIA), |
| BECTON, DICKINSON AND COMPANY | United States | Public Company | Medical Essentials (needles, syringes, vascular access, sharps safety),Connected Care (infusion, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery systems), |
| DIASORIN SPA | Italy | Public Company | Immunodiagnostics – LIAISON XL/XS infectious and GI disease panels,Immunodiagnostics – endocrinology, metabolic, tumor markers, oncology,Molecular diagnostics – Simplexa and LIAISON PLEX respiratory, |
| REVVITY | United States | Public Company | Diagnostics (prenatal, newborn, infectious disease, autoimmune, specialty IVD),Life science reagents, assay platforms, and genomic workflows,Instruments, imaging, detection systems, and software, |
| TOSOH CORPORATION | Japan | Public Company | Basic chemicals (caustic soda, sodium bicarbonate, calcium hypochlorite, related chlor-alkali),Petrochemicals and polymers (VCM, PVC, polyethylene, EVA, synthetic rubber, functional polymers),Polyurethanes and related intermediates (MDI, HDI, polyisocyanates, polyols, PU resins), |
| QUIDEL CORPORATION | United States | Public Company | Labs (Clinical Chemistry & Immunoassay),Transfusion Medicine,Point of Care, |
| GUANGZHOU WONDFO BIOTECH CO., LTD. | China | Public Company | Rapid test kits (COVID-19, infectious disease, fertility, drug-of-abuse, tumor markers, STD),Immunofluorescence platform (Finecare FIA Meter X2 and related assays),Chemiluminescence platform, |
ABBOTT LABORATORIES
Abbott Laboratories is a major United States-based public company founded in 1888 with approximately 115,000 employees, operating as a diversified healthcare organization.
DANAHER CORPORATION
Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees, operating across multiple industrial and life sciences sectors.
SIEMENS HEALTHINEERS AG
Siemens Healthineers AG is a German public company founded in 1896 with 72,369 employees, specializing in medical technology and healthcare solutions.
THERMO FISHER SCIENTIFIC
Thermo Fisher Scientific is a United States-based public company founded in 1956 with 125,000 employees, serving as a global leader in life sciences and laboratory services.
BIO-RAD LABORATORIES
Bio-Rad Laboratories is a United States-based public company founded in 1952 with 7,450 employees, specializing in life science research and clinical diagnostics products.
BIOMéRIEUX SA
bioMérieux SA is a French public company founded in 1963 with 14,894 employees, focused on in vitro diagnostics and microbiology testing solutions.
BECTON, DICKINSON AND COMPANY
Becton, Dickinson and Company is a United States-based public company founded in 1897 with 72,000 employees, specializing in medical devices, diagnostics, and biosciences.
DIASORIN SPA
DiaSorin SpA is an Italian public company founded in 1968 with 3,242 employees, specializing in in vitro diagnostics and immunodiagnostic solutions.
REVVITY
Revvity is a United States-based public company founded in 1937 with 11,000 employees, providing analytical instruments and life sciences solutions.
TOSOH CORPORATION
Tosoh Corporation is a Japanese public company founded in 1935 with 14,850 employees, operating across specialty chemicals, pharmaceuticals, and diagnostics sectors.
QUIDEL CORPORATION
Quidel Corporation is a United States-based public company founded in 1979 with 6,500 employees, specializing in rapid diagnostic testing solutions.
GUANGZHOU WONDFO BIOTECH CO., LTD.
Guangzhou Wondfo Biotech Co., Ltd. is a Chinese public company founded in 1992 with 2,443 employees, focused on in vitro diagnostic products and solutions.
Reasons to Buy this Report
- Regional Market Sizing : Obtain precise market valuation for Rest Of Latin America (USD 27.4M in 2026) with detailed forecasts through 2031, enabling accurate budget allocation and regional expansion planning.
- Growth Opportunity Assessment : Understand the 6.5% CAGR trajectory specific to Rest Of Latin America, identifying emerging opportunities in secondary and tertiary care facilities with growing diagnostic capacity.
- Competitive Landscape Intelligence : Gain insights into Rest Of Latin America's unique market dynamics, healthcare infrastructure gaps, and competitive positioning to inform market entry or expansion strategies.
- Healthcare Investment Trends : Access data on regional healthcare infrastructure investments and cardiovascular disease prevalence driving cardiac marker testing adoption across Rest Of Latin America.
- Strategic Decision Support : Leverage Rest Of Latin America-specific market intelligence to support product development, pricing strategies, and distribution channel optimization for regional success.
Frequently asked questions
What is the market size of cardiac marker testing in Rest Of Latin America?
Rest Of Latin America's cardiac marker testing market is estimated at USD 27.4 million in 2026 and is projected to reach USD 37.6 million by 2031.
What is the expected growth rate for cardiac marker testing in Rest Of Latin America?
Rest Of Latin America's cardiac marker testing market is expected to grow at a CAGR of 6.5% from 2026 to 2031.
Which testing technologies are gaining traction in Rest Of Latin America?
Rest Of Latin America is experiencing increased adoption of high-sensitivity troponin assays, multiplex testing platforms, and point-of-care diagnostic solutions.
What factors are driving growth in Rest Of Latin America's cardiac marker testing market?
Rest Of Latin America's market growth is driven by rising cardiovascular disease prevalence, improved healthcare infrastructure, regulatory advancements, and increased awareness of early cardiac event detection.
How is Rest Of Latin America's market evolving between 2026 and 2031?
Rest Of Latin America will see accelerated adoption of automated testing systems, shift toward high-sensitivity assays, and expansion of point-of-care testing capabilities in hospital and laboratory settings.
RESEARCH METHODOLOGY
The objective of the study is to analyze the key market dynamics, including drivers, opportunities, restraints, challenges, and strategies of key players. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players. The competitive landscape of the cardiac marker testing market analyzes market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches are used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation have been used.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
BREAKDOWN OF PRIMARY INTERVIEW PARTICIPANTS
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = > USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
|
COMPANY NAME |
DESIGNATION |
|
Abbott Laboratories (US) |
Sales Manager |
|
F. Hoffmann-La Roche AG (Switzerland) |
Product Manager |
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the cardiac marker testing market. These methods were also used extensively to estimate the sizes of various market subsegments. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the cardiac marker testing market have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
The research methodology used to estimate the market size includes the following:
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Cardiac marker testing refers to the measurement and quantification of biological parameters, such as enzymes, hormones, and proteins that are released into the bloodstream or show altered levels in response to cardiac conditions. These tests serve as indicators of the heart's physiological and pathophysiological status and are used for the early detection, risk stratification, and monitoring of cardiovascular diseases, including acute coronary syndrome (ACS), acute myocardial infarction (AMI), cardiac ischemia, and congestive heart failure (CHF).
Key Stakeholders
- Product Manufacturers, Distributors, and Suppliers
- Diagnostic Laboratories and Point-of-care Testing Centers
- Research Laboratories and CROs
- Ambulatory Testing Centers
- Contract Testing Laboratories
- Academic Universities and Medical Research Centers
- Research & Development (R&D) Centers
Report Objectives
- To define, segment, and forecast the cardiac marker testing market by product, technology, indication, biomarker type, point of testing, assay format, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
- To study the impact of AI on the market, along with the macroeconomic outlook for each region
Available customizations:
MarketsandMarkets offers the following customizations for this market report.
Country Information
- Additional country-level analysis of the cardiac marker testing market
Company profiles
- Additional five company profiles of players operating in the cardiac marker testing market.
Product Analysis
- Product matrix, which provides a detailed comparison of the product portfolio of each company in the cardiac marker testing market
Get the Full Cardiac Marker Testing Market Report
Full forecast, segment splits, and company analysis for all Cardiac Marker Testing Market.
- US Cardiac Marker Testing Market
- Canada Cardiac Marker Testing Market
- UK Cardiac Marker Testing Market
- Germany Cardiac Marker Testing Market
- France Cardiac Marker Testing Market
- Italy Cardiac Marker Testing Market
- Spain Cardiac Marker Testing Market
- China Cardiac Marker Testing Market
- Japan Cardiac Marker Testing Market
- India Cardiac Marker Testing Market
- Australia Cardiac Marker Testing Market
- South Korea Cardiac Marker Testing Market
- Brazil Cardiac Marker Testing Market
- Mexico Cardiac Marker Testing Market
- Rest Of Europe Cardiac Marker Testing Market
- Rest Of Asia Pacific Cardiac Marker Testing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report